Clinical update on sildenafil citrate

British Journal of Clinical Pharmacology

Volumn 53, Issue 3, 2002, Pages 219-223

  Osterloh, Ian H ^a   Riley, Alan ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

Author keywords

Efficacy; Prescribing information; Safety; Sildenafil

Indexed keywords

NITRATE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 6; PHOSPHODIESTERASE V; RITONAVIR; SILDENAFIL; UNCLASSIFIED DRUG;

BLOOD FLOW; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG USE; EDITORIAL; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FEMALE SEXUAL DYSFUNCTION; FLUSHING; HEADACHE; HEART INFARCTION; HEMODYNAMICS; HUMAN; INCIDENCE; INDIGESTION; INFERTILITY; NOSE CONGESTION; PAIN; PRESCRIPTION; PRIAPISM; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REIMBURSEMENT; SEXUAL AROUSAL; SEXUAL BEHAVIOR; SEXUAL FUNCTION; VISUAL DISORDER;

CLINICAL TRIALS; FEMALE; HUMANS; IMPOTENCE; MALE; PIPERAZINES; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; VASODILATOR AGENTS;

EID: 0036123840     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2002.bjcpxxx.doc.x     Document Type: Editorial

References (58)

1. The international men's health movement
2. Sildenafil citrate and blood-pressure-lowering drugs: Results of drug interaction studies with an organic nitrate and a calcium antagonist
3. Sidenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina
4. Sildenafil effects on human vascular function, platelet activation and myocardial ischaemia
5. Phosphodiesterase 5 inhibition. Effects on the coronary vasculature
6. Viagra® does not exacerbate ischemia, but renders platelets refractory to the inhibitory effects of adenosine
7. Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise
8. Effect of sildenafil on coronary active and reactive hyperemia
9. Effects of sildenafil citrate (Viagra) combined with nitrate on the heart
10. Hemodynamic effects of sildenafil in men with severe coronary artery disease
11. Ergometric studies for evaluating sildenafil effect in cardiac patients
12. Effects of phosphodiesterase-5 inhibition on myocardial ischemia in patients with chronic stable angina in therapy with beta-blockers
13. Beneficial effects of a phosphodiesterase type 5 inhibitor (sildenafil) on exercise, neurohormonal activation, and erectile dysfunction in patients with congestive heart failure: A double-blind placebo-controlled cross-over randomised study
14. Is sildenafil (Viagra®) safe and effective for the treatment of erectile dysfunction in patients with heart failure?
15. Acute type 5-phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure
16. Efficacy and safety of Viagra (sildenafil citrate) in patients with erectile dysfunction taking concomitant antihypertensive therapy
17. Sildenafil (Viagra) and cardiac patients: An open outpatient study
18. Sildenafil (Viagra®) improves the elastic properties of the aorta
19. Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease
20. Effects of sildenafil (Viagra®) on cardiovascular autonomic function (CAF) in man: Preliminary results
21. Cardiovascular events in users of sildenafil: Results from first phase of prescription event monitoring in England
22. The use of sildenafil in heart disease
23. Effects of sildenafil citrate on human hemodynamics
24. Vaginal sildenafil (Viagra). A preliminary report of a novel method to improve uterine artery blood flow and endometrial development in patients undergoing IVF
25. Selectivity of sildenafil citrate and other phosphodiesterase type 5 (PDE5) inhibitors against human phosphodiesterase types 7-11
26. Treatment of erectile dysfunction in men with depressive symptoms: Results of a placebo-controlled trial with sildenafil citrate
27. Viagra (sildenafil citrate) for the treatment of erectile dysfunction in men with multiple sclerosis
28. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in Parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension
29. Erectile dysfunction in patients with spina bifida is a treatable condition
30. Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate
31. Sildenafil citrate (Viagra®) and erectile dysfunction following external beam radiotherapy for prostate cancer. A randomised double-blind placebo-controlled crossover study
32. Efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dysfunction
33. Time dependent patient satisfaction with sildenafil citrate for erectile dysfunction after nerve-sparing radical retropubic prostatectomy
34. Sildenafil in the treatment of erectile dysfunction after radical prostatectomy
35. Incidence of erectile dysfunction and efficacy of sildenafil in the cardiac transplantation patient
36. Treatment with sildenafil citrate in renal transplant patients with erectile dysfunction
37. Long-term efficacy of sildenafil and tachyphylaxis effect
38. Assessment of the efficacy and safety of Viagra (sildenafil citrate) in men with erectile dysfunction during long-term treatment
39. Efficacy and safety of Viagra® in estrogenized women with sexual dysfunction associated with female sexual arousal disorder (FSAD)
40. A pilot study of the effect of Viagra® on vaginal blood flow (VBF) in female subjects
41. Premenopausal women affected by sexual arousal disorder treated with sildenafil: A double-blind, cross-over, placebo-controlled study
42. Sildenafil in primary pulmonary hypertension
43. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal
44. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension
45. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors
46. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment
47. Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction
48. The effect of the specific phosphodiesterase (PDE) inhibitors on human and rabbit cavernous tissue in vitro and in vivo
49. Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current
50. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir
51. Incidence of myocardial infarction and death in 53 clinical trials of Viagra (sildenafil citrate)
52. Cost utility analysis of sildenafil compared with papaverine-phentolamine injections
53. The cost-effectiveness of sildenafil
54. Viagra and rationing. Let the sunlight in, let the people speak
55. Viagra: A botched test case for rationing
56. 'No change for guidelines on GP prescribing of NHS impotence treatments' (No sex please, we're New Labour)